Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Free Cash Flow (2016 - 2025)

SRx Health Solutions (SRXH) has disclosed Free Cash Flow for 16 consecutive years, with -$15.7 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Free Cash Flow fell 4010.7% year-over-year to -$15.7 million, compared with a TTM value of -$13.9 million through Sep 2025, down 430.08%, and an annual FY2023 reading of $79000.0, up 100.38% over the prior year.
  • Free Cash Flow was -$15.7 million for Q2 2025 at SRx Health Solutions, down from $377000.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $1.5 million in Q4 2024 and bottomed at -$15.7 million in Q2 2025.
  • Average Free Cash Flow over 5 years is -$2.8 million, with a median of -$2.3 million recorded in 2021.
  • The sharpest move saw Free Cash Flow skyrocketed 138.09% in 2023, then plummeted 4010.7% in 2025.
  • Year by year, Free Cash Flow stood at -$3.8 million in 2021, then soared by 31.48% to -$2.6 million in 2022, then surged by 138.09% to $983000.0 in 2023, then surged by 48.83% to $1.5 million in 2024, then tumbled by 1176.14% to -$15.7 million in 2025.
  • Business Quant data shows Free Cash Flow for SRXH at -$15.7 million in Q2 2025, $377000.0 in Q1 2025, and $1.5 million in Q4 2024.